Biomerica, Inc.
BMRA
Rank in Stocks
#29684
Biomerica, Inc. is a biomedical technology firm that invents, secures... Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Share Price
$1.55
Last synced: 2026-11-09
Market Cap
$7.13M
Change (1 day)
-3.73%
Change (1 year)
-38.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Biomerica, Inc. (BMRA)
Category
Healthcare
Operating Margin for Biomerica, Inc. (BMRA)
Operating Margin as of November 2026 TTM: -125.22%
According to Biomerica, Inc.'s latest financial reports, its current operating margin (TTM) is -125.22%. At the end of 2025 the company had an operating margin of -96.72%.
Operating Margin history for Biomerica, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -125.22% | 29.47% |
| 2025 | -96.72% | -17.74% |
| 2024 | -117.58% | -13.09% |
| 2023 | -135.29% | 463.00% |
| 2022 | -24.03% | -76.93% |
| 2021 | -104.18% | 190.19% |
| 2020 | -35.90% | -22.61% |
| 2019 | -46.39% | 74.20% |
| 2018 | -26.63% | 61.59% |
| 2017 | -16.48% | 2.42% |
| 2016 | -16.09% | 19.10% |
| 2015 | -13.51% | 54.93% |
| 2014 | -8.72% | -209.82% |
| 2013 | 7.94% | -4.34% |
| 2012 | 8.30% | -407.41% |
| 2011 | -2.70% | -62.40% |
| 2010 | -7.18% | -243.03% |
| 2009 | 5.02% | -51.45% |
| 2008 | 10.34% | 14.13% |
| 2007 | 9.06% | -771.11% |
| 2006 | -1.35% | -46.64% |
| 2005 | -2.53% | -26.67% |
| 2004 | -3.45% | 48.71% |
| 2003 | -2.32% | -57.12% |
| 2002 | -5.41% | -29.28% |
| 2001 | -7.65% | -85.33% |
| 2000 | -52.16% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.12% |
US
|
|
| 18.08% | -100.14% |
IE
|
|
| 21.25% | -100.17% |
US
|
|
| 21.05% | -100.17% |
US
|
|
| 28.09% | -100.22% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Biomerica, Inc.'s operating margin
What is Biomerica, Inc.'s operating margin?
Biomerica, Inc.'s operating margin is -125.22%, as of Nov 2026.
What was Biomerica, Inc.'s operating margin in 2025?
In 2025, Biomerica, Inc.'s operating margin was -96.72%, compared with -117.58% in 2024.
How has Biomerica, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Biomerica, Inc.'s operating margin was highest in 2022 (-24.03%) and lowest in 2023 (-135.29%).
How does Biomerica, Inc.'s operating margin compare with similar companies?
Biomerica, Inc.'s operating margin (-125.22%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.